C-Reactive Protein to Identify Early Risk for Development of Calcific Aortic Stenosis. Right Marker? Wrong Time?**Editorials published in the Journal of the American College of Cardiology reflect the views of the authors and do not necessarily represent the views of JACC or the American College of Cardiology.

Journal of the American College of Cardiology

Volumn 50, Issue 20, 2007, Pages 1999-2001

  Stone, Peter H ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

C REACTIVE PROTEIN; DIPEPTIDYL CARBOXYPEPTIDASE; LOW DENSITY LIPOPROTEIN; MATRIX METALLOPROTEINASE; PLACEBO; ROSUVASTATIN; TENASCIN;

AORTA STENOSIS; AORTA VALVE DISEASE; CARDIOVASCULAR RISK; DISEASE COURSE; DRUG MECHANISM; EDITORIAL; HUMAN; MORBIDITY; MORTALITY; PRIORITY JOURNAL;

AORTIC VALVE STENOSIS; BIOLOGICAL MARKERS; C-REACTIVE PROTEIN; CALCINOSIS; RISK FACTORS; TIME FACTORS;

EID: 35748976246     PISSN: 07351097     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jacc.2007.07.065     Document Type: Editorial

References (26)

1. Freeman R.V., and Otto C.M. Spectrum of calcific aortic valve disease: pathogenesis, disease progression, and treatment strategies. Circulation 111 (2005) 3316-3326
2. O'Brien K.D. Pathogenesis of calcific aortic valve disease: a disease process comes of age (and a good deal more). Arterioscler Thromb Vasc Biol 26 (2006) 1721-1728
3. Stewart B.F., Siscovick D., Lind B.K., et al. Clinical factors associated with calcific aortic valve disease. Cardiovascular Health Study. J Am Coll Cardiol 29 (1997) 630-634
4. Ridker P.M. Clinical application of C-reactive protein for cardiovascular disease detection and prevention. Circulation 107 (2003) 363-369
5. Novaro G.M., Katz R., Aviles R.J., et al. Clinical factors, but not C-reactive protein, predict progression of calcific aortic valve disease: the Cardiovascular Health Study. J Am Coll Cardiol 50 (2007) 1992-1999
6. Olsson M., Thyberg J., and Nilsson J. Presence of oxidized low density lipoprotein in nonrheumatic stenotic aortic valves. Arterioscler Thromb Vasc Biol 19 (1999) 1218-1222
7. Otto C.M., Kuusisto J., Reichenbach D.D., Gown A.M., and O'Brien K.D. Characterization of the early lesion of 'degenerative' valvular aortic stenosis. Histological and immunohistochemical studies. Circulation 90 (1994) 844-853
8. Satta J., Melkko J., Pollanen R., et al. Progression of human aortic valve stenosis is associated with tenascin-C expression. J Am Coll Cardiol 39 (2002) 96-101
9. Rajamannan N.M., Subramaniam M., Springett M., et al. Atorvastatin inhibits hypercholesterolemia-induced cellular proliferation and bone matrix production in the rabbit aortic valve. Circulation 105 (2002) 2660-2665
10. Helske S., Lindstedt K.A., Laine M., et al. Induction of local angiotensin II-producing systems in stenotic aortic valves. J Am Coll Cardiol 44 (2004) 1859-1866
11. Mohler III E.R., Chawla M.K., Chang A.W., et al. Identification and characterization of calcifying valve cells from human and canine aortic valves. J Heart Valve Dis 8 (1999) 254-260
12. Kaden J.J., Bickelhaupt S., Grobholz R., et al. Receptor activator of nuclear factor kappaB ligand and osteoprotegerin regulate aortic valve calcification. J Mol Cell Cardiol 36 (2004) 57-66
13. Pohle K., Maffert R., Ropers D., et al. Progression of aortic valve calcification: association with coronary atherosclerosis and cardiovascular risk factors. Circulation 104 (2001) 1927-1932
14. Otto C.M. Why is aortic sclerosis associated with adverse clinical outcomes?. J Am Coll Cardiol 43 (2004) 176-178
15. Newby D.E., Cowell S.J., and Boon N.A. Emerging medical treatments for aortic stenosis: statins, angiotensin converting enzyme inhibitors, or both?. Heart 92 (2006) 729-734
16. Moura L.M., Ramos S.F., Zamorano J.L., et al. Rosuvastatin affecting aortic valve endothelium to slow the progression of aortic stenosis. J Am Coll Cardiol 49 (2007) 554-561
17. Cowell S.J., Newby D.E., Prescott R.J., et al. A randomized trial of intensive lipid-lowering therapy in calcific aortic stenosis. N Engl J Med 352 (2005) 2389-2397
18. O'Brien K.D., Probstfield J.L., Caulfield M.T., et al. Angiotensin-converting enzyme inhibitors and change in aortic valve calcium. Arch Intern Med 165 (2005) 858-862
19. Rosenhek R., Rader F., Loho N., et al. Statins but not angiotensin-converting enzyme inhibitors delay progression of aortic stenosis. Circulation 110 (2004) 1291-1295
20. Skowasch D., Schrempf S., Preusse C.J., et al. Tissue resident C reactive protein in degenerative aortic valves: correlation with serum C reactive protein concentrations and modification by statins. Heart 92 (2006) 495-498
21. Galante A., Pietroiusti A., Vellini M., et al. C-reactive protein is increased in patients with degenerative aortic valvular stenosis. J Am Coll Cardiol 38 (2001) 1078-1082
22. Gerber I.L., Stewart R.A., Hammett C.J., et al. Effect of aortic valve replacement on C-reactive protein in nonrheumatic aortic stenosis. Am J Cardiol 92 (2003) 1129-1132
23. Venugopal S.K., Devaraj S., Yuhanna I., Shaul P., and Jialal I. Demonstration that C-reactive protein decreases eNOS expression and bioactivity in human aortic endothelial cells. Circulation 106 (2002) 1439-1441
24. Rifai N., Joubran R., Yu H., Asmi M., and Jouma M. Inflammatory markers in men with angiographically documented coronary heart disease. Clin Chem 45 (1999) 1967-1973
25. Khera A., de Lemos J.A., Peshock R.M., et al. Relationship between C-reactive protein and subclinical atherosclerosis: the Dallas Heart Study. Circulation 113 (2006) 38-43
26. Ortlepp J.R., Hoffmann R., Ohme F., Lauscher J., Bleckmann F., and Hanrath P. The vitamin D receptor genotype predisposes to the development of calcific aortic valve stenosis. Heart 85 (2001) 635-638